Modest growth for Bayer diagnostics:
This article was originally published in Clinica
Executive Summary
The diagnostics and diabetes care segment of Bayer HealthCare grew by 3.8% in the first quarter, to E461m ($586m). The company said negative currency effects reduced the growth by two percentage points. Diagnostics grew at 5% to E318m, driven by lab testing systems and near-patient testing. Diabetes care product sales of E143m were up by 1.4%, an increase the company attributed to a strong performance in Europe. Earnings before interest and tax rose by E9m to E37m. Bayer group sales were up 15.7% to E6.7bn, with EBIT before special items up 50.1% to E1.1bn.